The promise of genomics to identify novel therapeutic targets

Expert Opinion on Therapeutic Targets

Volumn 8, Issue 6, 2004, Pages 587-596

  Orth, Anthony P ^a   Batalov, Serge ^a   Perrone, Mark ^a   Chanda, Sumit K ^a  

^a GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

Author keywords

Drug discovery; Druggable genome; Functional genomics; Functional profiling; High throughput biology; Target identification; Target validation

Indexed keywords

COMPLEMENTARY DNA; CYCLIC AMP; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYTOCHROME P450; ERYTHROPOIETIN; G PROTEIN COUPLED RECEPTOR; GENE PRODUCT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIGANDIN; METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATE; PROTEIN P53; PROTEIN SERINE KINASE; PROTEIN TYROSINE KINASE; PROTEINASE; SMALL INTERFERING RNA; THREONINE PROTEINASE; TRANSCRIPTION FACTOR AP 1;

FUNCTIONAL GENOMICS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE LOCUS; GENE SEQUENCE; GENE TARGETING; GENETIC ANALYSIS; GENETIC DATABASE; GENETIC TRANSFECTION; HUMAN; IN VIVO STUDY; NONHUMAN; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; VALIDATION PROCESS;

ANIMALS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; FORECASTING; GENE EXPRESSION PROFILING; GENE TARGETING; GENOME, HUMAN; GENOMICS; HUMANS; ION CHANNELS; MICE; MICE, KNOCKOUT; MODELS, ANIMAL; MULTIGENE FAMILY; PROTEASE INHIBITORS; PROTEIN KINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 11144346764     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.8.6.587     Document Type: Review

References (81)

1. LANDER ES, LINTON LM, BIRREN B et al.: Initial sequencing and analysis of the human genome. Nature (2001) 409 860-921.
2. VENTER JC, ADAMS MD, MYERS EW et al.: The sequence of the human genome. Science (2001) 291:1304-1351.
3. WOODCOCK J, FEIGAL J, GOODMAN J et al.: Innovation or stagnation? - challenge and opportunity on the critical path to new medical products. FDA Report (2004)
4. ZAMBROWICZ BP, SANDS AT: Knockouts model the 100 best-selling drugs - will they model the next 100? Nat. Rev. Drug Discov. (2003) 2:38-51.
5. VINSON MC, DAVIS W, WATERS IW: New drug approvals of 2002-2003. Drug Topics (2002-2003).
6. HOPKINS AL, GROOM CR: The druggable genome. Nat. Rev. Drug Discov. (2002) 1:727-730.
7. MANNING G, WHYTE DB, MARTINEZ R et al.: The protein kinase complement of the human genome. Science (2002) 298 1912-1934.
8. YOUSEF GM, KOPOLOVIC AD, ELLIOTT MB et al.: Genomic overview of serine proteases. Biochem. Biophys. Res. Commun. (2003) 305:28-36.
9. SOUTHAN C: A genomic perspective on human proteases as drug targets. Drug Discov. Today (2001) 6:681-688.
10. MATHE C, SAGOT MF, SCHIEX T et al.: Current methods of gene prediction, their strengths and weaknesses. Nucleic Acids Res. (2002) 30:4103-4117.
11. MEYER IM, DURBIN R: Gene structure conservation aids similarity based gene prediction. Nucleic Acids Res. (2004) 32 776-783.
12. SHAH SP, MCVICKER GP, MACKWORTH AK et al.: GeneComber: combining outputs of gene prediction programs for improved results. Bioinformatics (2003) 19:1296-1297.
13. SOUTHAN C: Has the yo-yo stopped? An assessment of human protein-coding gene number. Proteomics (2004) 4:1712-1726.
14. MULDER NJ, APWEILER R, ATTWOOD TK et al.: The InterPro database, 2003 brings increased coverage and new features. Nucleic Acids Res. (2003) 31:315-318.
15. HEILIG R, ECKENBERG R, PETIT JL et al.: The DNA sequence and analysis of human chromosome 14. Nature (2003) 421 601-607.
16. HILLIER LW, FULTON RS, FULTON LA et al.: The DNA sequence of human chromosome 7. Nature (2003) 424:157-164.
17. ISTRAIL S, SUTTON GG, FLOREA L et al.: Whole-genome shotgun assembly and comparison of human genome assemblies. Proc. Natl. Acad. Sci. USA (2004) 101:1916-1921.
18. GIBBS RA, WEINSTOCK GM, METZKER ML et al.: Genome sequence of the Brown Norway rat yields insights into mammalian evolution. Nature (2004) 428:493-521.
19. OKAZAKI Y, FURUNO M, KASUKAWA T et al.: Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature (2002) 420:563-573.
20. ALONSO A, SASIN J, BOTTINI N et al.: Protein tyrosine phosphatases in the human genome. Cell (2004) 117:699-711.
21. PRUITT KD, KATZ KS, SICOTTE H et al.: Introducing RefSeq and LocusLink: curated human genome resources at the NCBI. Trends Genet. (2000) 16:44-47.
22. SALFELD JG: Use of new biotechnology to design rational drugs against newly defined targets. Best Pract. Res. Clin. Rheumatol. (2004) 18:81-95.
23. VASSILEV LT, VU BT, GRAVES B et al.: In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 303:844-848.
24. RILEY JH, ALLAN CJ, LAI E et al.: The use of single nucleotide polymorphisms in the isolation of common disease genes. Pharmacogenomics (2000) 1:39-47.
25. CHESLER EJ, LU L, WANG J et al.: WebQTL: rapid exploratory analysis of gene expression and genetic networks for brain and behavior. Nat. Neurosci. (2004) 7:485-486.
26. NO AUTHORS LISTED: The International HapMap Project. Nature (2003) 426:789-796.
27. BECKER KG, BARNES KC, BRIGHT TJ et al.: The genetic association database. Nat. Genet. (2004) 36:431-432.
28. FRIERSON HF Jr, MOSKALUK CA, POWELL SM et al.: Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum. Pathol. (2003) 34 605-609.
29. SU AI, COOKE MP, CHING KA et al.: Large-scale analysis of the human and mouse transcriptomes. Proc. Natl. Acad. Sci. USA (2002) 99:4465-4470.
30. HUANG Q, JIN X, GAILLARD ET et al.: Gene expression profiling reveals multiple toxicity endpoints induced by hepatotoxicants. Mutat. Res. (2004) 549:147-167.
31. VAN DE VIJVER MJ, HE YD, VAN'T VEER LJ et al.: A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. (2002) 347:1999-2009.
32. FRANK R, HARGREAVES R: Clinical biomarkers in drug discovery and development. Nat. Rev. Drug Discov. (2003) 2:566-580.
33. BUTTE A: The use and analysis of microarray data. Nat. Rev. Drug Discov. (2002) 1:951-960.
34. RHODES DR, YU J, SHANKER K et al.: Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc. Natl. Acad. Sci. USA (2004) 101:9309-9314.
35. CHOI JK, CHOI JY, KIM DG et al.: Integrative analysis of multiple gene expression profiles applied to liver cancer study. FEBS Lett. (2004) 565:93-100.
36. EDGAR R, DOMRACHEV M, LASH AE: Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. (2002) 30:207-210.
37. FIELDS S, SONG O: A novel genetic system to detect protein-protein interactions. Nature (1989) 340:245-246.
38. ALBALA JS: Array-based proteomics: the latest chip challenge. Expert Rev. Mol. Diagn. (2001) 1:145-152.
39. GLOKLER J, ANGENENDT P: Protein and antibody microarray technology. J. Chromatogr. B Analyst. Technol. Biomed. Life Sci. (2003) 797:229-240.
40. PANDEY A, MANN M: Proteomics to study genes and genomes. Nature (2000) 405:837-846.
41. HO Y, GRUHLER A, HEILBUT A et al.: Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry. Nature (2002) 415:180-183.
42. GAVIN AC, BOSCHE M, KRAUSE R et al.: Functional organization of the yeast proteome by systematic analysis of protein complexes. Nature (2002) 415:141-147.
43. BOUWMEESTER T, BAUCH A, RUFFNER H et al.: A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway. Nat. Cell Biol. (2004) 6:97-105.
44. CHANDA SK, CALDWELL JS: Fulfilling the promise: drug discovery in the post-genomic era. Drug Discov. Today (2003) 8 168-174.
45. STRAUSBERG RL, FEINGOLD EA, GROUSE LH et al.: Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc. Natl. Acad. Sci. USA (2002) 99 16899-16903.
46. PADDISON PJ, SILVA JM, CONKLIN DS et al.: A resource for large-scale RNA-interference-based screens in mammals. Nature (2004) 428:427-431.
47. BERNS K, HIJMANS EM, MULLENDERS J et al.: A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature (2004) 428:431-437.
48. CHANDA SK, WHITE S, ORTH AP et al.: Genome-scale functional profiling of the mammalian AP-1 signaling pathway. Proc. Natl. Acad. Sci. USA (2003) 100:12153-12158.
49. CARPENTER AE, SABATINI DM: Systematic genome-wide screens of gene function. Nat. Rev. Genet. (2004) 5:11-22.
50. KUCKUCK FW, EDWARDS BS, SKLAR LA: High throughput flow cytometry. Cytometry (2001) 44:83-90.
51. EMPTAGE NJ: Fluorescent imaging in living systems. Curr. Opin. Pharmacol. (2001) 1:521-525.
52. CHAMBERS C, SMITH F, WILLIAMS C et al.: Measuring intracellular calcium fluxes in high throughput mode. Comb. Chem. High Throughput Screen. (2003) 6:355-362.
53. RUBIN H: The significance of biological heterogeneity. Cancer Metastasis Rev. (1990) 9:1-20.
54. PROSSER HR, ASTAN S: Manipulation of the mouse genome: a multiple impact resource for drug discovery and development. Trends Biotechnol. (2003) 21:224-232.
55. LINDSAY MA: Target discovery. Nat. Rev. Drug Discov. (2003) 2:831-838.
56. HUANG Q, RAYA A, DEJESUS P et al.: Identification of p53 regulators by genome-wide functional analysis. Proc. Natl. Acad. Sci. USA (2004) 101:3456-3461.
57. THOMAS KR, CAPECCHI MR: Targeted disruption of the murine int-1 proto-oncogene resulting in severe abnormalities in midbrain and cerebellar development. Nature (1990) 346:847-850.
58. GU H, MARTH JD, ORBAN PC et al.: Deletion of a DNA polymerase beta gene segment in T cells using cell type-specific gene targeting. Science (1994) 265:103-106.
59. TISCORNIA G, SINGER O, IKAWA M et al.: A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc. Natl. Acad. Sci. USA (2003) 100 1844-1848.
60. RUBINSON DA, DILLON CP, KWIATKOWSKI AV et al.: A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat. Genetics (2003) 33:401-406.
61. HERMAN GE: Mouse models of human disease: lessons learned and promises to come. ILAR J. (2002) 43:55-56.
62. HARDOUIN SN, NAGY A: Mouse models for human disease. Clin. Genet. (2000) 57:237-244.
63. GE H, WALHOUT AJVIDAL M: Integrating 'omic' information: a bridge between genomics and systems biology. Trends Genet. (2003) 19:551-560.
64. BEAUMONT MA, RANNALA B: The Bayesian revolution in genetics. Nat. Rev. Genet. (2004) 5:251-261.
65. FRIEDMAN N: Inferring cellular networks using probabilistic graphical models. Science (2004) 303:799-805.
66. MATSUDA A, SUZUKI Y, HONDA G et al.: Large-scale identification and characterization of human genes that activate NF-kappaB and MAPK signaling pathways. Oncogene (2003) 22 3307-3318.
67. ALBAYRAK T, GRIMM S: A high-throughput screen for single gene activities: isolation of apoptosis inducers. Biochem. Biophys. Res. Commun. (2003) 304:772-776.
68. CONKRIGHT MD, CANETTIERI G, SCREATON R et al.: TORCs: transducers of regulated CREB activity. Molecular Cell (2003) 12 413-423.
69. IOURGENKO V, ZHANG W, MICKANIN C et al.: Identification of a family of cAMP response element-binding protein coactivators by genome-scale functional analysis in mammalian cells. Proc. Natl. Acad Sci. USA (2003) 100:12147-12152.
70. CHEN C, GRZEGORZEWSKI KJ, BARASH S et al.: An integrated functional genomics screening program reveals a role for BMP-9 in glucose homeostasis. Nat. Biotechnology (2003) 21:294-301.
71. MICHIELS F, VAN ES H, VAN ROMPAEY L et al.: Arrayed adenoviral expression libraries for functional screening. Nat. Biotechnology (2002) 20:1154-1157.
72. FISCELLA M, PERRY JW, TENG B et al.: TIP, a T-cell fitctor identified using high-throughput screening increases survival in a graft-versus-host disease model. Nat. Biotechnology (2003) 21 302-307.
73. ZIAUDDIN J, SABATINI DM: Microarrays of cells expressing defined cDNAs. Nature (2001) 411:107-110.
74. BRUMMELKAMP TR, NIJMAN SM, DIRAC AM et al.: Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature (2003) 424:797-801.
75. ZHENG L, LIU J, BATALOV S et al.: An approach to genomewide screens of expressed small interfering RNAs in mammalian cells. Proc. Natl. Acad. Sci. USA (2004) 101:135-140.
76. AZA-BLANC P, COOPER CL, WAGNER K et al.: Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening. Molecular Cell (2003) 12:627-637.
77. HUSSAR DA: New drugs of 2003 J. Am. Pharm. Assoc. (2004) 44:168-206.
78. HUSSAR DA: New drugs of 2002. J. Am. Pharm. Assoc (Wash) (2003) 43:207-245.
79. GRAUL AI: The year's new drugs. Drug News Perspect. (2003) 16:22-39.
80. GRAUL AI: The year's new drugs. Drug News Perspect. (2004) 17:43-57.
81. PUENTE XS, SANCHEZ LM, OVERALL CM et al.: Human and mouse proteases: a comparative genomic approach. Nat. Rev. Genet. (2003) 4:544-558.